Cargando…

Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases

Recent studies suggested a potential of rituximab (RTX) in treating autoimmune thrombocytopenia (AITP) secondary to autoimmune diseases. In this study, we retrospectively evaluated the efficacy and safety of RTX therapy in patients with refractory AITP secondary to systemic lupus erythematosus (SLE)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Bin, Li, Ting, Guo, Li, Shen, Hao, Ye, Shuang, Chen, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539196/ https://www.ncbi.nlm.nih.gov/pubmed/26203828 http://dx.doi.org/10.1097/RHU.0000000000000273

Ejemplares similares

Rituximab Therapy for Refractory Autoimmune Thrombocytopenia in Patients with Systemic Lupus Erythematosus
por: Atay, Didem, et al.
Publicado: (2012)

Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus
por: Bang, So-Young, et al.
Publicado: (2012)

A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus
por: Zhang, Shuo, et al.
Publicado: (2021)

Steroid-Resistant Autoimmune Thrombocytopenia in Systemic Lupus Erythematosus Treated with Rituximab
por: Sardesai, Vasudha V, et al.
Publicado: (2015)

Splenectomy for refractory thrombocytopenia in juvenile systemic lupus erythematosus
por: Campos, LMA, et al.
Publicado: (2008)

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2014)

Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus
por: Penha, Mariana Álvares, et al.
Publicado: (2018)

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

Refractory Orbital Myositis in Systemic Lupus Erythematosus A Role for Rituximab
por: Rodrigues Morais, Joana, et al.
Publicado: (2021)

Eltrombopag Improves Refractory Thrombocytopenia in a Patient with Systemic Lupus Erythematosus
por: Shima, Natsuki, et al.
Publicado: (2018)

Rituximab induced acute thrombocytopenia in a patient with systemic lupus erythematosus: a case report
por: Yudhishdran, Jevon, et al.
Publicado: (2021)

Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study
por: Su, Kaisheng, et al.
Publicado: (2022)

Successful Treatment with Rituximab in a Patient with Castleman's Disease Complicated by Systemic Lupus Erythematosus and Severe Autoimmune Thrombocytopenia
por: Zhang, Lu, et al.
Publicado: (2015)

Safety and efficacy of rituximab in refractory pediatric Systemic Lupus Erythematosus nephritis: a single-center experience of northern Greece
por: Trachana, M, et al.
Publicado: (2011)

Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis
por: Wu, Shanshan, et al.
Publicado: (2020)

Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review
por: Machado, Roberta Ismael Lacerda, et al.
Publicado: (2014)

Successful Treatment of Refractory Thrombocytopenia with Mycophenolate Mofetil in a Patient with Systemic Lupus Erythematosus
por: Chang, Hyun Kyu
Publicado: (2005)

Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome
por: Xu, Liping, et al.
Publicado: (2022)

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
por: Cortés-Hernández, Josefina, et al.
Publicado: (2012)

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
por: McCarthy, Eoghan M, et al.
Publicado: (2018)

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
por: Hennessey, Ashleigh, et al.
Publicado: (2019)

Two Cases of Refractory Thrombocytopenia in Systemic Lupus Erythematosus that Responded to Intravenous Low-Dose Cyclophosphamide
por: Park, Hee-Jin, et al.
Publicado: (2013)

Sjögren’s syndrome and systemic lupus erythematosus: links and risks
por: Pasoto, Sandra Gofinet, et al.
Publicado: (2019)

Very Severe and Refractory Noninfectious Cystitis in Patients with Systemic Lupus Erythematosus: Potential Role of Rituximab Therapy
por: Ocampo-Piraquive, Vanessa, et al.
Publicado: (2021)

Refractory Bullous Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report and Literature Review
por: Ratanapokasatit, Yanisa, et al.
Publicado: (2023)

Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies
por: Petricca, Luca, et al.
Publicado: (2020)

Clinical effect and safety evaluation of different dosage of Rituximab combined with Cyclophosphamide in treatment of refractory immune Thrombocytopenia
por: Wang, Zhibin, et al.
Publicado: (2020)

Rituximab therapy for juvenile-onset systemic lupus erythematosus
por: Nwobi, Obioma, et al.
Publicado: (2007)

Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

Analysis of rituximab’s usage for the treatment of pediatric systemic lupus erythematosus
por: Alves, Alessandra, et al.
Publicado: (2014)

Thrombotic thrombocytopenic purpura treated with rituximab in systemic lupus erythematosus
por: Karimifar, Mansoor
Publicado: (2012)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

HLA DR-DQ haplotypes and genotypes in patients with systemic lupus erythematosus with co-existing Sjogren's syndrome, systemic lupus erythematosus without Sjogren's syndrome and primary Sjogren's syndrome: clinical and laboratory associations
por: Georgopoulou, Ch, et al.
Publicado: (2005)

Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis
por: Suh, Chang-Hee
Publicado: (2022)

Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus
por: Li, Jie, et al.
Publicado: (2018)

A case of developing progressive multifocal leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory systemic lupus erythematosus
por: Ishikawa, Yuichi, et al.
Publicado: (2018)

Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia
por: Ahn, Soo Min, et al.
Publicado: (2022)

The interconnected roles of TRIM21/Ro52 in systemic lupus erythematosus, primary Sjögren’s syndrome, cancers, and cancer metabolism
por: Hsu, Chueh-Hsuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7pl864o0guokfh8go7015etvhr